The Cytochrome P450 System: What Is It and Why Should I Care?

January 2011
Davis's Drug Guide for Nurses, 12th Edition;2011, p1440
Information on the cytochrome P450, the liver's enzyme system, is presented.


Related Articles

  • Cytochrome P450 Enzymes. Guengerich, F. Peter // American Scientist;Sep/Oct93, Vol. 81 Issue 5, p440 

    Provides information on the capability of cytochrome P450 enzymes to defend the human body against environmental pollutants, detoxify drugs and synthesize several important signaling molecules. Chemicals that the enzymes detoxify; Role of cytochrome P450 enzymes in the metabolism of endogenous...

  • Enzyme Kinetics of Cytochrome P450-Mediated Reactions. Magang Shou, A.; Yuh Lin, A.; Ping Lu; Cuyue Tang, A.; Qin Mei, A.; Dan Cui, A.; Wei Tang; Ngui, Jason S.; Lin, C. Charles; Singh, Rominder; Wong, Bradley K.; Yergey, James A.; Lin, Jiunn H.; Pearson, Paul G.; Baillie, Thomas A.; Rodrigues, A. David; Rushmore, Thomas H. // Current Drug Metabolism;Mar2001, Vol. 2 Issue 1, p17 

    The most common drug-drug interactions may be understood in terms of alterations of metabolism, associated primarily with changes in the activity of cytochrome P450 (CYP) enzymes. Kinetic parameters such as K m , V max , K i and K a , which describe metabolism-based drug interactions, are...

  • Polymorphic CYP2A6 and its clinical and toxicological significance. Rautio, A // Pharmacogenomics Journal;2003, Vol. 3 Issue 1, p5 

    Explains the clinical and toxicological significance of the polymorphic cytochrome P450 (CYP) enzymes, specifically CYP2A6. Review of related studies; Mechanism of action of the enzyme; Implications for pharmacology.

  • Kidney CYP450 Enzymes: Biological Actions Beyond Drug Metabolism. Zhao, X.; Imig, J.D. // Current Drug Metabolism;Feb2003, Vol. 4 Issue 1, p73 

    Arachidonic acid can be metabolized by cytochrome P450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosatrienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE). These arachidonic acid metabolites are involved in...

  • Prediction of Human Drug Metabolizing Enzyme Induction. Mankowski, Dayna C.; Ekins, Sean // Current Drug Metabolism;Oct2003, Vol. 4 Issue 5, p381 

    New chemical entities are routinely screened in vitro and in vivo for their ability to induce cytochrome P450s (CYP), other drug-metabolizing enzymes and possibly transporters in an attempt to more accurately predict clinical parameters such as drug-drug interactions and clearance in humans....

  • Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues. Pavek, Petr; Dvorak, Zdenek // Current Drug Metabolism;Feb2008, Vol. 9 Issue 2, p129 

    Numerous members of the cytochrome P450 (CYP) superfamily are induced after exposure to a variety of xenobiotics in human liver. We have gained considerable mechanistic insights into these processes in hepatocytes and multiple ligand-activated transcription factors have been identified over the...

  • Human Cytochromes P450 Associated with the Phase 1 Metabolism of Drugs and other Xenobiotics: A Compilation of Substrates and Inhibitors of the CYP1, CYP2 and CYP3 Families. Lewis, David F.V. // Current Medicinal Chemistry;Oct2003, Vol. 10 Issue 19, p1955 

    This review represents a compilation of typical substrates and inhibitors for human cytochrome P450 (CYP) enzymes that are involved in drug metabolism, specifically those from the CYP1, CYP2 and CYP3 families. Relatively recent literature on substrates and inhibitors has been collected and the...

  • Atazanavir. Goldsmith, David R.; Perry, Caroline M. // Drugs;2003, Vol. 63 Issue 16, p1679 

    â–´ Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. â–´ The resistance profile of atazanavir is distinct, with an I50L protease substitution appearing to be the signature mutation. â–´ Atazanavir was not associated...

  • Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Wadelius, M; Sörlin, K; Wallerman, O; Karlsson, J; Yue, Q-Y; Magnusson, PKE; Wadelius, C; Melhus, H // Pharmacogenomics Journal;2004, Vol. 4 Issue 1, p40 

    The required dose of the oral anticoagulant warfarin varies greatly, and overdosing often leads to bleeding. Warfarin is metabolised by cytochrome P450 enzymes CYP2C9, CYP1A2 and CYP3A. The target cell level of warfarin may be dependent on the efflux pump P-glycoprotein, encoded by the adenosine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics